Michael G. Rolf

R&d
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Corrigendum to "Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As" [J. Pharmacol. Toxicol. Methods 123 (2023) 107270].

Corrigendum to "Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As" [J. Pharmacol. Toxicol. Methods 123 (2023) 107270].

Journal: Journal of pharmacological and toxicological methods

Published: September 16, 2025

Rodent home cage monitoring for preclinical safety pharmacology assessment: results of a multi-company validation evaluating nonclinical and clinical data from three compounds.

Rodent home cage monitoring for preclinical safety pharmacology assessment: results of a multi-company validation evaluating nonclinical and clinical data from three compounds.

Journal: Frontiers in toxicology

Published: June 27, 2025

Current practices on the measurement of electrocardiogram and hemodynamic parameters in non-rodent species in regulatory safety assessment studies.

Current practices on the measurement of electrocardiogram and hemodynamic parameters in non-rodent species in regulatory safety assessment studies.

Journal: Journal of pharmacological and toxicological methods

Published: April 07, 2025

On the relationship between hERG inhibition and the magnitude of QTc prolongation: An in vitro to clinical translational analysis.

On the relationship between hERG inhibition and the magnitude of QTc prolongation: An in vitro to clinical translational analysis.

Journal: Toxicology and applied pharmacology

Published: September 16, 2024

Modelling hemodynamics regulation in rats and dogs to facilitate drugs safety risk assessment.

Modelling hemodynamics regulation in rats and dogs to facilitate drugs safety risk assessment.

Journal: Frontiers in pharmacology

Published: March 17, 2024

Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.

Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.

Journal: Journal of pharmacological and toxicological methods

Published: February 20, 2023

GABAA receptor-mediated seizure liabilities: a mixed-methods screening approach.

GABAA receptor-mediated seizure liabilities: a mixed-methods screening approach.

Journal: Cell biology and toxicology

Published: December 08, 2022

Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.

Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.

Journal: Clinical pharmacology and therapeutics

Published: June 02, 2020

Current and future approaches to nonclinical cardiovascular safety assessment.

Current and future approaches to nonclinical cardiovascular safety assessment.

Journal: Drug discovery today

Published: December 13, 2019

Femoral Head Growth Plate Dysplasia and Fracture in Juvenile Rabbits Induced by Off-target Antiangiogenic Treatment.

Femoral Head Growth Plate Dysplasia and Fracture in Juvenile Rabbits Induced by Off-target Antiangiogenic Treatment.

Journal: Toxicologic pathology

Published: May 11, 2016

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.

Journal: Pharmacology research & perspectives

Published: April 09, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026